JP2019509265A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509265A5
JP2019509265A5 JP2018541394A JP2018541394A JP2019509265A5 JP 2019509265 A5 JP2019509265 A5 JP 2019509265A5 JP 2018541394 A JP2018541394 A JP 2018541394A JP 2018541394 A JP2018541394 A JP 2018541394A JP 2019509265 A5 JP2019509265 A5 JP 2019509265A5
Authority
JP
Japan
Prior art keywords
tumor
motomeko
cells
recombinant
cells according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018541394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/017588 external-priority patent/WO2017139725A1/en
Publication of JP2019509265A publication Critical patent/JP2019509265A/ja
Publication of JP2019509265A5 publication Critical patent/JP2019509265A5/ja
Pending legal-status Critical Current

Links

JP2018541394A 2016-02-11 2017-02-12 二重標的化によるアデノウイルスの皮下送達 Pending JP2019509265A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294251P 2016-02-11 2016-02-11
US62/294,251 2016-02-11
US201662294987P 2016-02-12 2016-02-12
US62/294,987 2016-02-12
PCT/US2017/017588 WO2017139725A1 (en) 2016-02-11 2017-02-12 Subcutaneous delivery of adenovirus with dual targeting

Publications (2)

Publication Number Publication Date
JP2019509265A JP2019509265A (ja) 2019-04-04
JP2019509265A5 true JP2019509265A5 (cg-RX-API-DMAC7.html) 2020-03-19

Family

ID=59563571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018541394A Pending JP2019509265A (ja) 2016-02-11 2017-02-12 二重標的化によるアデノウイルスの皮下送達

Country Status (9)

Country Link
US (2) US20190091316A1 (cg-RX-API-DMAC7.html)
EP (1) EP3413909A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019509265A (cg-RX-API-DMAC7.html)
KR (1) KR20180102707A (cg-RX-API-DMAC7.html)
CN (1) CN109069598A (cg-RX-API-DMAC7.html)
AU (1) AU2017218445A1 (cg-RX-API-DMAC7.html)
CA (1) CA3014056A1 (cg-RX-API-DMAC7.html)
IL (1) IL261037A (cg-RX-API-DMAC7.html)
WO (1) WO2017139725A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735984A1 (en) * 2016-05-27 2020-11-11 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
KR20210010678A (ko) 2016-06-30 2021-01-27 난트 홀딩스 아이피, 엘엘씨 난트 암 백신
US12653874B2 (en) 2016-06-30 2026-06-16 Immunitybio, Inc. Nant cancer vaccine
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
US20220133823A1 (en) * 2018-09-10 2022-05-05 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
KR101114784B1 (ko) * 2002-11-12 2012-02-27 예일 유니버시티 아데노바이러스 벡터 백신
FR2993716B1 (fr) * 2012-07-20 2016-09-02 Thales Sa Antenne d'emission et de reception multifaisceaux a plusieurs sources par faisceau, systeme d'antennes et systeme de telecommunication par satellite comportant une telle antenne
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy

Similar Documents

Publication Publication Date Title
Sun et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells
JP6928380B2 (ja) B7タンパク質をコードする腫瘍溶解性アデノウイルス
Diehl et al. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway
Morgan et al. Adoptive cell therapy: genetic modification to redirect effector cell specificity
Chen et al. XCL1/glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti–PD-1 efficacy
US20220185861A1 (en) Methods and compositions for treating cancer
US20100240585A1 (en) In vivo cell surface engineering
AU2017233072B2 (en) Multimodal vector for dendritic cell infection
Zamarin et al. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
CN109952309A (zh) 用于细胞治疗的组成型活性细胞因子受体
Strbo et al. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases
CN112154204A (zh) 基因工程化的细胞及应用
CN111868077A (zh) Gpi锚定抗原的增强的免疫原性
JP2019524773A (ja) 樹状細胞のトランスフェクション及びその方法
AU2017218445A1 (en) Subcutaneous delivery of adenovirus with dual targeting
CN108085340A (zh) 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体
JP2020532287A (ja) 癌の治療のためのネオアンチゲンワクチン組成物
Xu et al. T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
Ragonnaud et al. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression
Schmittnaegel et al. A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells
Xie et al. Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application
CN115397439A (zh) 表达通用免疫受体的工程化细胞活性的定量控制
Truscott et al. Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides
Gato-Cañas et al. Novel immunotherapies for the treatment of melanoma
WO2025049742A1 (en) Systems and methods for generating multivalent mosaic hla nanoparticles for personalized immunotherapy applications